Recent advances in our understanding of Streptococcus pneumoniae infection

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Feldman, Charles ^a   Anderson, Ronald ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; VIRULENCE FACTOR;

ANTIMICROBIAL THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; IMMUNIZATION; MEDICAL CARE; PNEUMOCOCCAL COMMUNITY ACQUIRED PNEUMONIA; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

STREPTOCOCCUS PNEUMONIAE;

EID: 84907045428     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-82     Document Type: Article

References (81)

1. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A: The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012, 21:57-65.
2. Said MA, Johnson HL, Nonyane, Bareng A S, Deloria-Knoll M, O'Brien KL, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratalà J, Chang F, Charles, Patrick G P, Diaz AA, Domínguez J, Ehara N, Endeman H, Falcó V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman, Andy I M, Hohenthal U, Johansson N, Kolek V et al.: Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE 2013, 8:e60273.
3. Feldman C, Anderson R: Antibiotic resistance of pathogens causing community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:232-43.
4. Low DE: What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?). Infect Dis Clin North Am 2013, 27:87-97.
5. Steel HC, Cockeran R, Anderson R, Feldman C: Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm 2013, 2013:490346.
6. Feldman C, Anderson R: Respiratory Infections in Specific Populations: HIV Patients. In Respiratory Infections in Specific Populations. Edited by Blasi F. Delhi: Jaypee Brothers (in press).
7. Fauci AS, Morens DM: The perpetual challenge of infectious diseases. N Engl J Med 2012, 366:454-61.
8. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M et al.: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-128.
9. Sanz Herrero F, Blanquer Olivas J: Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:220-31.
10. Cillóniz C, Ewig S, Menéndez R, Ferrer M, Polverino E, Reyes S, Gabarrús A, Marcos MA, Cordoba J, Mensa J, Torres A: Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect 2012, 65:223-30.
11. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, Albaya A, Cerdá E, Catalán RM, Luque P, Paredes A, Navarrete I, Rello J, Rodríguez A: Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011, 139:555-62.
12. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, Higgs E, Randolph AG, Smoot BE, Thompson BT: Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012, 40:1487-98.
13. Muscedere J, Ofner M, Kumar A, Long J, Lamontagne F, Cook D, Mc Geer A, Chant C, Marshall J, Jouvet P, Fowler R: The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection. Chest 2013, 144: 39-47.
14. Rodrigo C, Lim WS: The relevance of pneumococcal serotypes. Curr Infect Dis Rep 2014, 16:403.
15. Weinberger DM, Harboe ZB, Sanders, Elisabeth A M, Ndiritu M, Klugman KP, Rückinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, O'Brien KL, Scott JA, Lipsitch M: Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010, 51:692-9.
16. Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, Riesbeck K: High incidence of septic shock caused by Streptococcus pneumoniae serotype 3-a retrospective epidemiological study. BMC Infect Dis 2013, 13:492.
17. Song JY, Nahm MH, Moseley MA: Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 2013, 28:4-15.
18. Rello J, Lisboa T, Lujan M, Gallego M, Kee C, Kay I, Lopez D, Waterer GW: Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009, 136:832-40.
19. Werno AM, Anderson TP, Murdoch DR: Association between pneumococcal load and disease severity in adults with pneumonia. J Med Microbiol 2012, 61:1129-35.
20. Seedat MA, Feldman C, Skoularigis J, Promnitz DA, Smith C, Zwi S: A study of acute community-acquired pneumonia, including details of cardiac changes. Q J Med 1993, 86:669-75.
21. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ: Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012, 125:773-81.
22. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA: Acute pneumonia and the cardiovascular system. Lancet 2013, 381:496-505.
23. Musher DM, Rueda AM, Kaka AS, Mapara SM: The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007, 45:158-65.
24. Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratalà J: Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013, 66:27-33.
25. Eurich DT, Johnstone JJ, Minhas-Sandhu JK, Marrie TJ, Majumdar SR: Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study. Heart 2012, 98:1072-7.
26. Niederman MS, Luna CM: Community-acquired pneumonia guidelines: a global perspective. Semin Respir Crit Care Med 2012, 33:298-310.
27. Caballero J, Rello J: Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care 2011, 1:48.
28. Asadi L, Eurich DT, Gamble J, Minhas-Sandhu JK, Marrie TJ, Majumdar SR: Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 2012, 106:451-8.
29. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR: Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012, 55:371-80.
30. Metersky ML, Ma A, Houck PM, Bratzler DW: Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007, 131:466-73.
31. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR: Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014, 42:420-32.
32. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid M, Bernadete F, Hui DS, Andremont A, Chiou, Christine C C: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-4.
33. Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C: Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm 2012, 2012:584262.
34. Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M, Kim KS, Jenkinson HF, Nau R, Hammerschmidt S: PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun 2005, 73:2680-9.
35. Yamaguchi M, Terao Y, Mori-Yamaguchi Y, Domon H, Sakaue Y, Yagi T, Nishino K, Yamaguchi A, Nizet V, Kawabata S: Streptococcus pneumoniae invades erythrocytes and utilizes them to evade human innate immunity. PLoS ONE 2013, 8:e77282.
36. Mandell GL, Coleman E: Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001, 45:1794-8.
37. Hirst RA, Mohammed BJ, Mitchell TJ, Andrew PW, O'Callaghan C: Streptococcus pneumoniae-induced inhibition of rat ependymal cilia is attenuated by antipneumolysin antibody. Infect Immun 2004, 72:6694-8.
38. Wunderink RG, Mandell L: Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:311-8.
39. Ramaiah SK, Jaeschke H: Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol 2007, 35:757-66.
40. Vanaudenaerde BM, Wuyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets S, Van Raemdonck D E, Verleden GM: Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007, 7:76-82.
41. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, Tokue Y, Watanabe A, Nukiwa T: Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002, 49:745-55.
42. Li M, Zhong X, He Z, Wen M, Li J, Peng X, Liu G, Deng J, Zhang J, Bai J: Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-κB activity in human macrophages in vitro. Int Immunopharmacol 2012, 12:643-50.
43. Amado-Rodríguez L, González-López A, López-Alonso I, Aguirre A, Astudillo A, Batalla-Solís E, Blazquez-Prieto J, García-Prieto E, Albaiceta GM: Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. Respir Res 2013, 14:52.
44. Karlström A, Boyd KL, English BK, McCullers JA: Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009, 199:311-9.
45. Majhi A, Kundu K, Adhikary R, Banerjee M, Mahanti S, Basu A, Bishayi B: Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice. J Inflamm (Lond) 2014, 11:5.
46. Lynch JP, Zhanel GG: Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009, 30:210-38.
47. Cockeran R, Steel HC, Wolter N, de Gouveia L, von Gottberg A, Klugman KP, Leanord AT, Inverarity DJ, Mitchell TJ, Feldman C, Anderson R: Effects of clarithromycin at sub-minimum inhibitory concentrations on early ermB gene expression, metabolic activity and growth of an erm(B)-expressing macrolide-resistant strain of Streptococcus pneumoniae. Open Journal of Respiratory Diseases 2012, 2:1-8.
48. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI, Rello J: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-20.
49. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33:153-9.
50. Kohno S, Tateda K, Kadota J, Fujita J, Niki Y, Watanabe A, Nagashima M: Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia. J Infect Chemother 2014, 20:199-207.
51. Walkey AJ, Wiener RS: Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012, 141:1153-9.
52. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR: Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012, 55:371-80.
53. Sligl WI, Hoang H, Eurich DT, Malhotra A, Marrie TJ, Majumdar SR: Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes. Can J Infect Dis Med Microbiol 2013, 24:e107-12.
54. Laserna E, Sibila O, Fernandez JF, Maselli DJ, Mortensen EM, Anzueto A, Waterer G, Restrepo MI: Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia. Chest 2014, 145:1114-20.
55. Brouwer MC, Heckenberg S G B, Gans J de, Spanjaard L, Reitsma JB, van de Beek D: Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010, 75:1533-9.
56. Borchorst S, Møller K: The role of dexamethasone in the treatment of bacterial meningitis - a systematic review. Acta Anaesthesiol Scand 2012, 56:1210-21.
57. Prasad K, Rai NK, Kumar A: Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults. Curr Infect Dis Rep 2012, 14:445-53.
58. Brouwer MC, McIntyre P, Prasad K, van de Beek Diederik: Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013, 6:CD004405.
59. Heckenberg , Sebastiaan G B, Brouwer MC, van de Beek Diederik: Bacterial meningitis. Handb Clin Neurol 2014, 121:1361-75.
60. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-8.
61. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J: Effects of systemic steroids in patients with severe commu-nity- acquired pneumonia. Eur Respir J 2007, 30:951-6.
62. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, Narumoto O, Kichikawa Y, Kawai M, Tashimo H, Arai H, Horiuchi T, Sakamoto Y: Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007, 185:249-55.
63. Nagy B, Gaspar I, Papp A, Bene Z, Voko Z, Balla G: Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatr Pulmonol 2013, 48:168-75.
64. Snijders D, Daniels, Johannes M A, de Graaff, Casper S, van der Werf, Tjip S, Boersma WG: Efficacy of corticosteroids in community-acquired pneumonia: a randomized doubleblinded clinical trial. Am J Respir Crit Care Med 2010, 181:975-82.
65. Polverino E, Cillóniz C, Dambrava P, Gabarrús A, Ferrer M, Agustí C, Prina E, Montull B, Menendez R, Niederman MS, Torres A: Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. Respirology 2013, 18:263-71.
66. Barnes PJ: New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007, 119:1055-62; quiz 1063-4.
67. Kolditz M, Höffken G, Martus P, Rohde G, Schütte H, Bals R, Suttorp N, Pletz MW: Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis 2012, 12:90.
68. Mira E, Mañes S: Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets 2009, 9:237-47.
69. Leung P, Wang S, Lu S, Chou W, Shiau C, Chou T: Simvastatin inhibits pro-inflammatory mediators through induction of heme oxygenase-1 expression in lipopolysaccharide-stimulated RAW264.7 macrophages. Toxicol Lett 2011, 207:159-66.
70. Corrales-Medina VF, Musher DM: Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 2011, 63:187-99.
71. Troeman D P R, Postma DF, van Werkhoven C H, Oosterheert JJ: The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review. J Infect 2013, 67:93-101.
72. Doshi SM, Kulkarni PA, Liao JM, Rueda AM, Musher DM: The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013, 345:173-7.
73. Chopra V, Rogers, Mary A M, Buist M, Govindan S, Lindenauer PK, Saint S, Flanders SA: Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012, 125:1111-23.
74. Ginsburg AS, Alderson MR: New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011, 47:207-14.
75. Alicino C, Barberis I, Orsi A, Durando P: Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 - valent polysaccharide conjugate vaccine. Minerva Med 2014, 105:89-97.
76. Centers for Disease Control and Prevention (CDC): Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-9.
77. Pfizer: News/Press Releases. [http://www.pfizer.com/news/press-release-detail/pfizer]
78. Weinberger DM, Malley R, Lipsitch M: Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-73.
79. Ginsburg AS, Alderson MR: New conjugate vaccines for the prevention of pneumococcal disease in developing countries. Drugs Today 2011, 47:207-14.
80. Temime L, Boelle P, Opatowski L, Guillemot D: Impact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population. PLoS ONE 2008, 3:e3244.
81. Wyres KL, Lambertsen LM, Croucher NJ, McGee L, Gottberg A von, Liñares J, Jacobs MR, Kristinsson KG, Beall BW, Klugman KP, Parkhill J, Hakenbeck R, Bentley SD, Brueggemann AB: Pneumococcal capsular switching: a historical perspective. J Infect Dis 2013, 207:439-49.